File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Heterologous MVA-S prime Ad5-S boost regimen induces high and persistent levels of neutralizing antibody response against SARS coronavirus

TitleHeterologous MVA-S prime Ad5-S boost regimen induces high and persistent levels of neutralizing antibody response against SARS coronavirus
Authors
Issue Date2007
PublisherSpringer. The Journal's web site is located at http://link.springer.de/link/service/journals/00253/index.htm
Citation
Applied Microbiology And Biotechnology, 2007, v. 76 n. 5, p. 1131-1136 How to Cite?
AbstractSevere acute respiratory syndrome (SARS) is caused by a novel coronavirus (CoV), SARS-CoV. In previous studies, we showed that a SARS-CoV spike (S) glycoprotein-based modified vaccinia Ankara (MVA-S) vaccine could induce strong neutralizing antibody (Nab) response which might have played a critical role in protecting Chinese rhesus monkeys from the pathogenic viral challenge. To date, however, it remains unknown what the minimal level of Nab is required to achieve sterile immunity in humans. It is therefore important to explore techniques to maximize the level of Nab response in vivo. Here, we evaluate various vaccination regimens using combinations of DNA-S, MVA-S, and adenovirus type 5 (Ad5-S) vaccines. We show that in vaccinated mice and rabbits, a heterologous MVA-S prime with Ad5-S boost regimen induces the highest and most persistent level of Nab response when compared with other combinations. Interestingly, the initial level of Nab after prime does not necessarily predict the magnitude of the secondary response after the boost. Thus, our data provides a promising optimal regimen for vaccine development in humans against SARS-CoV infection. © 2007 Springer-Verlag.
Persistent Identifierhttp://hdl.handle.net/10722/85474
ISSN
2015 Impact Factor: 3.376
2015 SCImago Journal Rankings: 1.262
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorBa, Len_HK
dc.contributor.authorYi, CEen_HK
dc.contributor.authorZhang, Len_HK
dc.contributor.authorHo, DDen_HK
dc.contributor.authorChen, Zen_HK
dc.date.accessioned2010-09-06T09:05:28Z-
dc.date.available2010-09-06T09:05:28Z-
dc.date.issued2007en_HK
dc.identifier.citationApplied Microbiology And Biotechnology, 2007, v. 76 n. 5, p. 1131-1136en_HK
dc.identifier.issn0175-7598en_HK
dc.identifier.urihttp://hdl.handle.net/10722/85474-
dc.description.abstractSevere acute respiratory syndrome (SARS) is caused by a novel coronavirus (CoV), SARS-CoV. In previous studies, we showed that a SARS-CoV spike (S) glycoprotein-based modified vaccinia Ankara (MVA-S) vaccine could induce strong neutralizing antibody (Nab) response which might have played a critical role in protecting Chinese rhesus monkeys from the pathogenic viral challenge. To date, however, it remains unknown what the minimal level of Nab is required to achieve sterile immunity in humans. It is therefore important to explore techniques to maximize the level of Nab response in vivo. Here, we evaluate various vaccination regimens using combinations of DNA-S, MVA-S, and adenovirus type 5 (Ad5-S) vaccines. We show that in vaccinated mice and rabbits, a heterologous MVA-S prime with Ad5-S boost regimen induces the highest and most persistent level of Nab response when compared with other combinations. Interestingly, the initial level of Nab after prime does not necessarily predict the magnitude of the secondary response after the boost. Thus, our data provides a promising optimal regimen for vaccine development in humans against SARS-CoV infection. © 2007 Springer-Verlag.en_HK
dc.languageengen_HK
dc.publisherSpringer. The Journal's web site is located at http://link.springer.de/link/service/journals/00253/index.htmen_HK
dc.relation.ispartofApplied Microbiology and Biotechnologyen_HK
dc.subject.meshAdenoviruses, Human - genetics - immunologyen_HK
dc.subject.meshAnimalsen_HK
dc.subject.meshAntibodies, Viral - blooden_HK
dc.subject.meshFemaleen_HK
dc.subject.meshImmunizationen_HK
dc.subject.meshImmunization, Secondaryen_HK
dc.subject.meshMembrane Glycoproteins - genetics - immunology - metabolismen_HK
dc.subject.meshMiceen_HK
dc.subject.meshMice, Inbred BALB Cen_HK
dc.subject.meshNeutralization Testsen_HK
dc.subject.meshRabbitsen_HK
dc.subject.meshSARS Virus - immunologyen_HK
dc.subject.meshSevere Acute Respiratory Syndrome - immunology - prevention & control - virologyen_HK
dc.subject.meshVaccines, DNA - administration & dosage - immunologyen_HK
dc.subject.meshVaccinia virus - genetics - immunologyen_HK
dc.subject.meshViral Envelope Proteins - genetics - immunology - metabolismen_HK
dc.subject.meshViral Vaccines - administration & dosage - genetics - immunologyen_HK
dc.titleHeterologous MVA-S prime Ad5-S boost regimen induces high and persistent levels of neutralizing antibody response against SARS coronavirusen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0175-7598&volume=75&spage=1131&epage=6&date=2007&atitle=Heterologous+MVA-S+prime+Ad5-S+boost+regimen+induces+high+and+persistent+levels+of+neutralizing+antibody+response+against+SARS+coronavirusen_HK
dc.identifier.emailChen, Z:zchenai@hkucc.hku.hken_HK
dc.identifier.authorityChen, Z=rp00243en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1007/s00253-007-1073-yen_HK
dc.identifier.pmid17581748-
dc.identifier.scopuseid_2-s2.0-34548686141en_HK
dc.identifier.hkuros147739en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-34548686141&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume76en_HK
dc.identifier.issue5en_HK
dc.identifier.spage1131en_HK
dc.identifier.epage1136en_HK
dc.identifier.isiWOS:000249522500019-
dc.publisher.placeGermanyen_HK
dc.identifier.scopusauthoridBa, L=8557032300en_HK
dc.identifier.scopusauthoridYi, CE=8557032800en_HK
dc.identifier.scopusauthoridZhang, L=8783285300en_HK
dc.identifier.scopusauthoridHo, DD=7402971998en_HK
dc.identifier.scopusauthoridChen, Z=35271180800en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats